Discover Ono Pharmaceutical's groundbreaking patent for autophagy-inhibiting compounds, targeting various cancers with innovative MEK inhibitors like selumetinib.

Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, saying the drug could help prevent patients progressing to critical-stage ...

MEK Inhibitor-Based Treatments and FDA Approval of Selumetinib (Koselugo) Several clinical trials have investigated the effectiveness of drugs called MEK inhibitors as potential treatments for ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a ...

Ruscetti's previous research demonstrated that two cancer drugs (MEK inhibitor trametinib and CDK4/6 inhibitor palbociclib, or T/P) can promote blood vessel development, enabling greater T cell ...

Innovative use of lipid nanoparticles to deliver immune agonists shows promise in activating anti-tumor immunity in ...

They highlighted a type of cancer drug called MEK inhibitors, which work by blocking specific proteins from growing, as a potential candidate. And tests, conducted by the researchers, found MEK ...

Combined MEK and PI3K inhibition has had limited success in the clinic, although alternative methods of targeting these pathways may be effective. MEK inhibitors form the backbone of multiple ...

Ruscetti’s previous research had demonstrated that two cancer drugs, the MEK inhibitor trametinib and CDK4/6 inhibitor palbociclib (T/P in combination), can promote blood vessel development ...